Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
暂无分享,去创建一个
L. Constine | D. Friedman | R. Sposto | W. London | C. Schwartz | C. Tebbi | P. D. de Alarcon | N. Mendenhall | A. Chauvenet | D. Villaluna
[1] H. Prigerson,et al. Religiousness and spiritual support among advanced cancer patients and associations with end-of-life treatment preferences and quality of life. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] P. Voûte,et al. Second malignant neoplasms following childhood Hodgkin's disease: treatment and splenectomy as risk factors. , 2006, Medical and pediatric oncology.
[3] W. London,et al. Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: A Pediatric Oncology Group (POG) study , 2006, Pediatric blood & cancer.
[4] J. Berger,et al. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[5] M. Stovall,et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. , 2003, JAMA.
[6] A. Broeks,et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. , 2003, Journal of the National Cancer Institute.
[7] Anthony Lynch,et al. Investigations into the concept of a threshold for topoisomerase inhibitor-induced clastogenicity. , 2003, Mutagenesis.
[8] D. Nelson,et al. Risk of breast cancer and breast cancer characteristics in women treated with supradiaphragmatic radiation for Hodgkin lymphoma: Mayo Clinic experience. , 2003, Mayo Clinic proceedings.
[9] R. Pötter,et al. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. , 2003, Klinische Padiatrie.
[10] P. Davis,et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Jais,et al. Fifteen‐year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high‐dose irradiation , 2002, British journal of haematology.
[12] S. Jhanwar,et al. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy‐related myelodysplastic syndromes and acute leukemia: Report from an International Workshop † , 2002, Genes, chromosomes & cancer.
[13] F. Hosoda,et al. A Pediatric Case of Secondary Leukemia Associated with t(16;21)(q24;q22) Exhibiting the Chimeric AML1-MTG16 Gene , 2002, Leukemia & lymphoma.
[14] L. Robison,et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. , 2001, Journal of the National Cancer Institute.
[15] G. Leverger,et al. Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] K. Sugimoto,et al. Inhibition of p34cdc2 dephosphorylation in DNA damage‐ and topoisomerase II inactivation‐induced G2 arrests in HL‐60 cells , 1999, British journal of haematology.
[17] B. Freidlin,et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Hudson,et al. Increased mortality after successful treatment for Hodgkin's disease. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. L. Le Beau,et al. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors? , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] K. Shinohara,et al. A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, and the alkylating agent, cyclophosphamide. , 1998, International journal of hematology.
[21] J. Harbott,et al. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Sawyer,et al. Secondary acute myelogenous leukemia following safe exposure to etoposide. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] S. Swain,et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] F. Mandelli,et al. Acute nonlymphocytic leukemia: onset after treatment for Hodgkin's disease , 1997, Annals of Hematology.
[25] B. Phillips,et al. Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. , 1996, Biopharmaceutics & drug disposition.
[26] L. Robison,et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. , 1996, The New England journal of medicine.
[27] S. Steinberg,et al. Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] C. Felix,et al. ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. , 1995, Blood.
[29] V. Ferrans,et al. Morphologic and morphometric evaluation of the effect of ICRF-187 on bleomycin-induced pulmonary toxicity. , 1995, Toxicology.
[30] A. Hagenbeek,et al. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] A. Hagenbeek,et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] H. Tilly,et al. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] N R Schneider,et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] D. Lu,et al. Specific chromosomal translocations and therapy-related leukemia induced by bimolane therapy for psoriasis. , 1992, Leukemia research.
[35] F. Behm,et al. Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] M. Ro̸rth,et al. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours , 1991, The Lancet.
[37] J. Whitlock,et al. Epipodophyllotoxin‐related leukemia. Identification of a new subset of secondary leukemia , 1991, Cancer.
[38] L. Constine,et al. Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin's disease in children: a report from the Children's Cancer Study Group. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] N. Day,et al. Leukemia following Hodgkin's disease. , 1990, The New England journal of medicine.
[40] F. Behm,et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. , 1989, The New England journal of medicine.
[41] V. Ferrans,et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. , 1988, The New England journal of medicine.
[42] H. Hansen,et al. RISK OF THERAPY-RELATED LEUKAEMIA AND PRELEUKAEMIA AFTER HODGKIN'S DISEASE Relation to Age, Cumulative Dose of Alkylating Agents, and Time from Chemotherapy , 1987, The Lancet.
[43] T. Baglin,et al. Therapy-related acute nonlymphocytic leukemia with inversion of chromosome 16 and a sustained remission. , 1987, Cancer genetics and cytogenetics.
[44] R. Hoover,et al. Leukemia after therapy with alkylating agents for childhood cancer. , 1987, Journal of the National Cancer Institute.
[45] W. Wood,et al. Breast cancer developing in four women cured of Hodgkin's disease , 1984, Cancer.
[46] A. Aisenberg. Acute nonlymphocytic leukemia after treatment for Hodgkin's disease. , 1983, The American journal of medicine.
[47] T. Lister,et al. Gonadal function in Hodgkin's disease: long-term follow-up of chemotherapy. , 1982, British medical journal.
[48] T. Pajak,et al. Second malignant neoplasms in patients successfully treated for Hodgkin's disease: a Cancer and Leukemia Group B study. , 1982, Cancer treatment reports.
[49] A. Santoro,et al. Alternating drug combinations in the treatment of advanced Hodgkin's disease. , 1982, The New England journal of medicine.
[50] R. Schilsky,et al. Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. , 1981, The American journal of medicine.
[51] E. Glatstein,et al. Hematologic neoplasia in patients treated for Hodgkin's disease. , 1977, The New England journal of medicine.
[52] M. Lacher,et al. LEUKEMIA AND HODGKIN'S DISEASE. , 1963, Annals of internal medicine.
[53] S. Swink,et al. Doxorubicin inhibits human DNA topoisomerase I , 2004, Cancer Chemotherapy and Pharmacology.
[54] S. Tucker,et al. Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. , 2003, International journal of radiation oncology, biology, physics.
[55] R. Gray. A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .
[56] N. Breslow,et al. Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. , 1987, IARC scientific publications.